ZIOPHARM Oncology Inc (NASDAQ:ZIOP) closed at $3.83 on Friday


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) rose by 9.43%. The shares opened at a price of $3.59, which touched the intraday high of $3.88 and headed to a close of $3.83. Around 1.68 million exchanged hands over the trading day and an average volume of 1.61 million shares were traded over a 30 day period. The 52-week low of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) shares is $1.49 and its 52-week high is $5.95. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has a market capitalization of $375.27 million.                                        

About the company

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was incorporated on 16 May 2005. It  is a bio-technology company. it employs gene-expression & control-technology to deliver deoxyribonucleic-acid for cancer treatment. Its technology employsthe  Intrexon Corporation’s RheoSwitch Therapeutic-System to turn on & off &  precisely modulate, gene-expression at the cancer-site to improve the therapeutic-index.

As of 18 October 2013, the company’s technology was under evaluation in Phase-II clinical-studies of the immune-system cytokine interleukin-12 for treating breast cancer & advanced melanoma. It is also developing small-molecules as a potential cancer therapeutic.

In partnership with Intrexon, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is developing 2  clinical-stage DNA-therapeutics & is exploring numerous applications for this same revolutionary-technology in the lab. This includes the controlled-production in the body of therapeutic-antibodies, immune-toxins & protein decoys. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has multiple programs under its development. it also expects to file a minimum of 8 different IND applications right through to the year 2015. The recent data that has been presented at the 2013 AACR/NCI/EORTC meeting by ZIOPHARM Oncology Inc (NASDAQ:ZIOP) highlighted the potential use of skeletal-muscle as the embedded -controllable bioreactor. This will be used  to generate the therapeutics for various tumor targeted therapy of single / multiple RTS®-regulated cancer-immunotherapies which have the potential to be translated into an effective clinical regimen in cancer treatment.